Filing Details
- Accession Number:
- 0001209191-19-028235
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-05-08 16:35:09
- Reporting Period:
- 2019-05-06
- Accepted Time:
- 2019-05-08 16:35:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1293971 | Bluebird Bio Inc. | BLUE | Biological Products, (No Disgnostic Substances) (2836) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1578696 | David Davidson | C/O Bluebird Bio, Inc. 60 Binney Street Cambridge MA 02142 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-05-06 | 6,360 | $5.50 | 37,976 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-05-06 | 2,700 | $138.25 | 35,276 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-05-06 | 2,600 | $139.24 | 32,676 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2019-05-06 | 1,060 | $140.02 | 31,616 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-05-06 | 6,360 | $0.00 | 6,360 | $5.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 330 | 2023-01-16 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on January 10, 2019.
- The range in prices for the transaction reported on this line was $137.69 to $138.66. The average weighted price was $138.2471. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $138.70 to $139.69. The average weighted price was $139.2437. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was $139.70 to $140.53. The average weighted price was $140.0164. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This option to purchase shares of our common stock was granted on January 16, 2013 with performance-based vesting criteria that were met as of January 1, 2013, April 1, 2013 and May 1, 2013. The shares underlying these options vested as follows: 25% vested on January 1, 2014, April 1, 2014 and May 1, 2014, respectively, with the remainder of the shares vesting in equal monthly installments over the following three years.
Billionaire Hedge Funds
